Related references
Note: Only part of the references are listed.Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Neurologic complications of immune checkpoint inhibitors
Andreas F. Hottinger
CURRENT OPINION IN NEUROLOGY (2016)
CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review
Kavitha Kothur et al.
CYTOKINE (2016)
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report
Ryota Tanaka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
Tanya J. Williams et al.
JAMA NEUROLOGY (2016)
Biomarkers for neuromyelitis optica
Kuo-Hsuan Chang et al.
CLINICA CHIMICA ACTA (2015)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Bing Liao et al.
NEURO-ONCOLOGY (2014)
Bevacizumab Diminishes Experimental Autoimmune Encephalomyelitis by Inhibiting Spinal Cord Angiogenesis and Reducing Peripheral T-Cell Responses
Carolyn J. MacMillan et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Serologic diagnosis of NMO A multicenter comparison of aquaporin-4-IgG assays
P. J. Waters et al.
NEUROLOGY (2012)
Evidence-based guideline update: Plasmapheresis in neurologic disorders Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
I. Cortese et al.
NEUROLOGY (2011)
Share Paper
